RT Journal Article
SR Electronic
T1 The impact of COVID-19 non-pharmaceutical interventions on the future dynamics of endemic infections
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.22.20137588
DO 10.1101/2020.06.22.20137588
A1 Rachel E. Baker
A1 Sang Woo Park
A1 Wenchang Yang
A1 Gabriel A. Vecchi
A1 C. Jessica E. Metcalf
A1 Bryan T. Grenfell
YR 2020
UL http://medrxiv.org/content/early/2020/06/23/2020.06.22.20137588.abstract
AB Non-pharmaceutical interventions (NPIs) have been employed to reduce the transmission of SARS-CoV-2, yet these measures are already having similar effects on other directly-transmitted, endemic diseases. Disruptions to the seasonal transmission patterns of these diseases may have consequences for the timing and severity of future outbreaks. Here we consider the implications of SARS-CoV-2 NPIs for two endemic infections circulating in the United States of America (USA): respiratory syncytial virus (RSV) and seasonal influenza. Using laboratory surveillance data from 2020, we estimate that RSV transmission declined by at least 20% in the USA at the start of the NPI period. We simulate future trajectories of both RSV and influenza, using an epidemic model. As susceptibility increases over the NPI period, we find that substantial outbreaks of RSV may occur in future years, with peak outbreaks likely occurring in the winter of 2021-2022. Results for influenza broadly echo this picture, but are more uncertain; future outbreaks are likely dependent on the transmissibility and evolutionary dynamics of circulating strains.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe US RSV hospitalization data are available from the Agency for Healthcare Research and Quality upon signing a data use agreement. Influenza surveillance data is publicly available from Centers for Disease Control and Prevention FluView Interactive. State-level RSV data is available from the public health departments of Minnesota, Florida, Oregon, Texas. https://www.distributor.hcup-us.ahrq.gov/ https://www.health.state.mn.us/diseases/flu/stats/flustats19.pdf http://www.floridahealth.gov/diseases-and-conditions/respiratory-syncytial-virus/_documents/2020-w19-rsv-summary.pdf https://www.oregon.gov/oha/PH/DISEASESCONDITIONS/COMMUNICABLEDISEASE/DISEASESURVEILLANCEDATA/Documents/RSV_Oregon-2016-17.pdf https://www.dshs.texas.gov/IDCU/disease/rsv/Data/2019-20/2019-20-RSV-by-DSHS-HSR-052020.pdf